EP0200383A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
An improved method for administering insulin
Assignee: Eli Lilly and Co
•
Filing: 1986-04-07
•
Granted: —
•
Expires: 2006-04-07
Abstract
Abstract A treatment of diabetes mellitus is described. The method comprises administering, via the nasal mucous membrane of a patient having diabetes mellitus, a pharmaceutically acceptable amount of an alkali metal salt, the ammonium salt, or the free acid of a substantially zinc-free insulin, optionally in the presence of an absorption enhancing agent.
Inventors
- 👤 Kenneth Shyan-Ell Su
- 👤 Kristina Marie Campanale
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-24 03:24
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/06; A61K47/26; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/28; A61K47/08; A61K47/10; A61K47/12; A61K47/14; A61K9/00; A61K9/0012; A61K9/0043
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
45 words
An intranasal pharmaceutical formulation containing insulin for the treatment of diabetes mellitus characterized in that said intranasal formulation is comprised of insulin as an alkali metal salt, the ammonium salt or the free acid of a substantially zinc-free insulin, and a pharmaceutically acceptable diluent therefor.
Claim 2
Dependent Claim
45 words
An intranasal pharmaceutical formulation containing insulin for the treatment of diabetes mellitus characterized in that said intranasal formulation is comprised of insulin as an alkali metal salt, the ammonium salt or the free acid of a substantially zinc-free insulin, and a pharmaceutically acceptable diluent therefor.
Claim 3
Dependent Claim
69 words
An intranasal pharmaceutical formulation as claimed in claim 1 characterized further in that it contains an absorption enhancing amount of at least one absorption enhancing agent selected from the group consisting of (1) oleic acid or an ester or salt thereof, (2) a liquid form sorbitan fatty acid ester, (3) a liquid form polyoxyethylene derivative of a sorbitan fatty acid ester, and (4) a liquid form hydroxypolyoxyethylene-polyoxypropylene- polyoxyethylene copolymer.
Claim 4
Dependent Claim
22 words
A formulation as claimed in claim 2 in which the absorption enhancing agent is oleic acid or an ester or salt thereof.
Claim 5
Dependent Claim
29 words
A formulation as claimed in claim 3 in which oleic acid is present in an amount of from about .25% to about 1% by weight of the final formulation.
Claim 6
Dependent Claim
25 words
A formulation as claimed in claim 2 in which the absorption enhancing agent is a liquid form polyoxyethylene derivative of a sorbitan fatty acid ester.
Claim 7
Dependent Claim
34 words
An intranasal formulation as claimed in claim 5 in which the absorption enhancing agent is Tween 85 present in an amount of from about .25% to about 1% by weight of the final formulation.
Claim 8
Dependent Claim
42 words
An intranasal formulation as claimed in claim 2 in which the absorption enhancing agent is present as a combination of (1) oleic acid or an ester or salt thereof and (2) a liquid form polyoxyethylene derivative of a sorbitan fatty acid ester.
Claim 9
Dependent Claim
39 words
An intranasal formulation as claimed in claim 7 in which the absorption enhancing agent is oleic acid and Tween 85 each present in an amount of from about .25% to about 1 % by weight of the final formulation.
Claim 10
Dependent Claim
21 words
An intranasal pharmaceutical formulation as claimed in any one of claims 1 to 8 in which the insulin is sodium insulin.
Claim 11
Dependent Claim
16 words
An intranasal pharmaceutical formulation as claimed in claim 9 in which the insulin is human insulin.
Claim 12
Dependent Claim
33 words
An intranasal pharmaceutical formulation which comprises oleic acid and Tween 85, each of which are present in an amount of about .5% by weight based upon the final formulation, and human sodium insulin.
Claim 13
Dependent Claim
33 words
An intranasal pharmaceutical formulation which comprises oleic acid and Tween 85, each of which are present in an amount of about .5% by weight based upon the final formulation, and human sodium insulin.
Claim 14
Dependent Claim
25 words
The ammonium salt, an alkali metal salt, or the free acid of a substantially zinc-free insulin for use in the intranasal treatment of diabetes mellitus.
Claim 15
Dependent Claim
25 words
The ammonium salt, an alkali metal salt, or the free acid of a substantially zinc-free insulin for use in the intranasal treatment of diabetes mellitus.
Claim 16
Dependent Claim
15 words
The sodium salt of an insulin for use in the intranasal treatment of diabetes mellitus.
Claim 17
Dependent Claim
15 words
The sodium salt of an insulin for use in the intranasal treatment of diabetes mellitus.
Claim 18
Dependent Claim
15 words
Human insulin as its sodium salt for use in the intranasal treatment of diabetes mellitus.
Claim 19
Dependent Claim
15 words
Human insulin as its sodium salt for use in the intranasal treatment of diabetes mellitus.
Claim 20
Dependent Claim
22 words
An intranasal formulation as claimed in any one of claims 1 to 11 for use in the intranasal treatment of diabetes mellitus.
Claim 21
Dependent Claim
32 words
The use of the ammonium salt, an alkali metal salt, or the free acid of a substantially zinc-free insulin for the manufacture of a medicament for the intranasal treatment of diabetes mellitus.
Claim 22
Dependent Claim
32 words
The use of the ammonium salt, an alkali metal salt, or the free acid of a substantially zinc-free insulin for the manufacture of a medicament for the intranasal treatment of diabetes mellitus.
Claim 23
Dependent Claim
18 words
The use claimed in claim 16 in which the insulin is in the form of its sodium salt.
Claim 24
Dependent Claim
13 words
The use claimed in claim 17 in which the insulin is human insulin.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.